Test your knowledge! New interactive patient case video 📺 ➡️ 61y Male ➡️Metastatic #CRC ➡️ Already received chemotherapy & monoclonal antibody Tx >> How would you manage his treatment 2nd, 3rd line, and beyond? Prof. AndreaSartoreBianchi takes you through an interactive patient case:

📣 GI CONNECT podcast episode 📣 ➡️ Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) Dr. Shubham Pant & Prof. Efrat Dotan MD discuss chemotherapy strategies that matter Conversation topics include: - Efficacy & safety profiles - Relevance of mode of delivery - Cause of

Test your knowledge! New interactive patient case video 📺 📷 61y Male 📷CRC 📷 Already received chemotherapy & monoclonal antibody Tx >> How would you manage his treatment 2nd, 3rd line, and beyond? Prof. AndreaSartoreBianchi takes you through an interactive patient case:

mPDAC: Chemotherapy strategies Animated video & slides 🎓 🔎 Learn about 1L Tx options, key trial data, role/appropriateness of targeted therapies Endorsed by ICAN, International Cancer Advocacy Network PanCAN Digestive Cancers Europe @natpancfdn Watch the video below 📺 ▶️ Get the slides & see video 2:

Later-line strategies in metastatic #colorectalcancer: rechallenge or switch? 📺 Interactive patient case video: cor2ed.com/gi-connect/pro… w/ Prof. AndreaSartoreBianchi 🤝 Endorsed by ICAN, International Cancer Advocacy Network Digestive Cancers Europe Supported by an Independent Educational Grant from Bayer #CRC #CRCSM #MedEd

New! #CRC #MedEd programme 🎓 ‘Later-line treatment strategies in metastatic colorectal cancer’ ✅ It’s important to use all available therapeutics for pts w/ advanced CRC But how can we determine who is suitable for rechallenge? 📺 Prof. AndreaSartoreBianchi takes you through an

The LEAP-012 study compared lenvatinib + pembrolizumab + TACE vs TACE alone in intermediate-stage hepatocellular carcinoma Check out this overview of the published results from HCC CONNECT #MedEd #Oncology #HCC

👴 Patient case: 61y male with #CRC progression following chemotherapy + monoclonal antibody treatment Which treatment decisions would you make for him, 2nd, 3rd line + beyond? Test your knowledge in this interactive patient case video from Prof. AndreaSartoreBianchi Later- line

Frontline Tx regimens in mPDAC should be individualised based on: 🔸performance status 🔸comorbidities 🔸risk of neuropathy 👉 FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles What else do HCPs need to know about

Pancreatic ductal adenocarcinoma (PDAC) is usually Dx’d at an advanced, incurable stage due to non-specific symptoms. It has an extremely poor prognosis 🎓 Learn more & explore chemotherapy strategies in metastatic PDAC A 2-part animated video series from medical experts Prof.

Pancreatic ductal adenocarcinoma (PDAC) is usually Dx’d at an advanced, incurable stage due to non-specific symptoms & it has an extremely poor prognosis 🎓 Learn more & explore chemotherapy strategies in metastatic PDAC A 2-part animated video series from medical experts Prof.

Discover the expanding role of immunotherapy use in HCC in this 4-part micro e-learning series from HCC CONNECT #MedEd #HCC #Oncology #GIOncology

📣 GI CONNECT podcast episode 📣 Chemotherapy strategies that matter in mPDAC ➡️ How to choose and optimise the different chemotherapeutic options at 1st & 2nd line w/ Prof. Dr. Shubham Pant + Prof. Efrat Dotan MD 📹 Watch the full video/listen on Spotify/Apple:

GI CONNECT podcast episode - Chemotherapy strategies that matter in mPDAC How to choose and optimise the different chemotherapeutic options at 1st & 2nd line w/ Prof. Dr. Shubham Pant + Prof. Efrat Dotan MD Endorsed by ICAN, International Cancer Advocacy Network Digestive Cancers Europe The National Pancreas Foundation PanCAN Supported by

New weekly Annals of Surgical Oncology featured the article: The Landmark Series: Minimally Invasive Pancreatic Resection for Ductal Adenocarcinoma, Updates, Trends, and Future Considerations. ow.ly/xWjr50WC42k #ASOFeaturedArticle

🎓 mPDAC animated video! Chemotherapy strategies for metastatic pancreatic ductal adenocarcinoma (mPDAC) Learn about: 🔸1st line chemotherapy options 🔸Key trial data 🔸Role of targeted therapies where appropriate w Prof. Eileen M O’Reilly Endorsed by ICAN, International Cancer Advocacy Network PanCAN

🎓 mPDAC animated video! Chemotherapy strategies for metastatic pancreatic ductal adenocarcinoma (mPDAC) Learn about: 🔸2nd line chemotherapy options 🔸Impact of early Txs on sequencing w/ Prof. Efrat Dotan MD Endorsed by ICAN, International Cancer Advocacy Network PanCAN Digestive Cancers Europe @natpancfdn Watch the

🔎 mPDAC is notoriously aggressive w/ a poor prognosis Patients are generally Dx’d w/ advanced-stage disease & require chemotherapy as soon as possible New podcast episode from Prof. Dr. Shubham Pant and Prof. Efrat Dotan MD! 📹 Highlights video in this post Listen to the full

Later-line treatment strategies in metastatic #colorectalcancer: Rechallenge vs switching What do HCPs need to know about later-line Tx options in metastatic #colorectalcancer? 📺 Video in this post >> w/ Prof. AndreaSartoreBianchi Clinical takeaways include: ✅ Advanced #CRC